#USA #Drug Delivery #Vinci Pharmaceuticals #EPIPLANT #Avon-By-The-Sea

Vinci Pharmaceuticals Secures Series A Funding of Over $8 Million for EPIPLANT™ Development

Introduction

Vinci Pharmaceuticals Inc., a company focused on ophthalmic products, has recently announced the closing of its Series A funding round, raising more than $8 million. This funding is pivotal for advancing the development of its pioneering drug delivery platform, EPIPLANT™, designed to enhance treatment for retinal diseases. With the addition of previous seed funding amounting to $8.5 million, Vinci Pharmaceuticals has raised a total exceeding $16.5 million for its operations.

Understanding EPIPLANT™

EPIPLANT™ is Vinci's proprietary platform that facilitates extended-release drug administration through episcleral implants. This groundbreaking technology aims to address the limitations of conventional intraocular injections, which often complicate effective treatment delivery to retinal tissues. The platform, developed under the expertise of Dr. Karl Csaky, MD, PhD, in collaboration with the Retina Foundation of the Southwest, promises a transformative impact in ophthalmology.

The Funding Round

The recent Series A funding round was spearheaded by Dynagrow Capital, LLLP, with additional support from MintPharma Capital. The funds are earmarked for a multitude of vital activities, including Good Manufacturing Practices (GMP) operations, quality control, marketing strategies, and, crucially, initial human clinical trials for EPIPLANT™. Planned for 2027, the Phase 1/2a clinical study will be the first to evaluate the safety and efficacy of this innovative administration system in humans.

Executive Perspectives

Philip A. Gioia, co-founder and CEO of Vinci Pharmaceuticals, expressed gratitude towards the investors and the board for their confidence in the potential of EPIPLANT™ to revolutionize treatment approaches for vision-threatening diseases. He emphasized that this funding marks a significant step towards initiating the first human trials, reinforcing the belief in its capacity to provide safe, prolonged drug delivery to retinal tissues.

Sarah Hassan, the CEO of Dynagrow Capital, highlighted the potential of EPIPLANT™ to be a game-changer for ophthalmologists and their patients facing the challenges of retinal diseases. With EPIPLANT™, there exists an opportunity to significantly enhance patient adherence to treatment by eliminating the burdens associated with traditional methods of injection.

Clinical and Therapeutic Impact

Vinci Pharmaceuticals has secured various patents for the EPIPLANT™ technology and is making progress towards launching its Phase 1/2a clinical trial set for 2027. The current drug delivery methods for retinal diseases predominantly involve direct ocular injections, often leading to challenges in achieving therapeutic concentrations in the retinal tissues. The EPIPLANT™ system is tailored to overcome these barriers by providing a sustained release of therapeutic agents from a bioerodible episcleral implant.

Future Directions

Dr. Richard Lindstrom from Minnesota Eye Consultants remarked on the advantages of EPIPLANT™, noting that it allows targeted drug concentrations to be delivered to the macula, positioning it as a superior alternative to the current standard of intravitreal injections. Furthermore, this innovative technology could also lead to new treatment avenues for retinal conditions that have limited or no current therapeutic options.

Looking ahead, Vinci Pharmaceuticals has set its sights on conducting a Phase 1/2a clinical trial for EPIPLANT™ in 2027. This system is designed to enhance the delivery of small molecules, paving the way for numerous applications across various retinal diseases.

About Vinci Pharmaceuticals

Vinci Pharmaceuticals Inc. is on the brink of entering clinical phases, driven by its innovative and exclusive platform aimed at developing ‘first-in-class’, ‘best-in-class’, and ‘unique’ therapeutic products that address critical unmet needs in retinal disease management.

Conclusion

With the closing of this critical funding round, Vinci Pharmaceuticals is positioned to make a substantial impact in the field of ophthalmology. The successful launch of the EPIPLANT™ platform not only represents a technological breakthrough but also aims to transform the experiences and outcomes for patients facing retinal diseases.